These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31071511)

  • 1. Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease.
    Gheibi S; Gouvarchin Ghaleh HE; Motlagh BM; Azarbayjani AF; Zarei L
    Biomed Pharmacother; 2019 Jul; 115():108938. PubMed ID: 31071511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.
    Ali MH; Messiha BA; Abdel-Latif HA
    Pharm Biol; 2016 Jul; 54(7):1198-208. PubMed ID: 26134756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
    Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
    Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of tiopronin against high fat diet-induced non-alcoholic steatohepatitis in rats.
    Wang JQ; Zou YH; Huang C; Lu C; Zhang L; Jin Y; Lü XW; Liu LP; Li J
    Acta Pharmacol Sin; 2012 Jun; 33(6):791-7. PubMed ID: 22543705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK.
    Wu P; Zhao J; Guo Y; Yu Y; Wu X; Xiao H
    Biochem Biophys Res Commun; 2020 Aug; 529(3):834-838. PubMed ID: 32595039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
    Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
    Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients.
    Mueller M; Castro RE; Thorell A; Marschall HU; Auer N; Herac M; Rodrigues CMP; Trauner M
    Liver Int; 2018 Mar; 38(3):523-531. PubMed ID: 28853202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New evidence for the therapeutic potential of curcumin to treat nonalcoholic fatty liver disease in humans.
    Inzaugarat ME; De Matteo E; Baz P; Lucero D; García CC; Gonzalez Ballerga E; Daruich J; Sorda JA; Wald MR; Cherñavsky AC
    PLoS One; 2017; 12(3):e0172900. PubMed ID: 28257515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatoprotective effects of Shilajit on high fat-diet induced non-alcoholic fatty liver disease (NAFLD) in rats.
    Ghezelbash B; Shahrokhi N; Khaksari M; Ghaderi-Pakdel F; Asadikaram G
    Horm Mol Biol Clin Investig; 2020 Feb; 41(1):. PubMed ID: 32083445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
    Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
    World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat.
    Jiang W; Guo MH; Hai X
    World J Gastroenterol; 2016 Dec; 22(46):10180-10188. PubMed ID: 28028366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of curcumin on visfatin and zinc-α2-glycoprotein in a rat model of non-alcoholic fatty liver disease.
    Li C; Li J; Chen Y; Zhong X; Kang M
    Acta Cir Bras; 2016 Nov; 31(11):706-713. PubMed ID: 27982256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
    Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
    J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatoprotective Effect of Seed Coat ofEuryale ferox Extract in Non-alcoholic Fatty Liver Disease Induced by High-fat Diet in Mice by Increasing IRs-1 and Inhibiting CYP2E1.
    Jian T; Yu C; Ding X; Chen J; Li J; Zuo Y; Ren B; Lv H; Li W
    J Oleo Sci; 2019 Jun; 68(6):581-589. PubMed ID: 31092797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does propolis have any effect on non-alcoholic fatty liver disease?
    Kismet K; Ozcan C; Kuru S; Gencay Celemli O; Celepli P; Senes M; Guclu T; Sorkun K; Hucumenoglu S; Besler T
    Biomed Pharmacother; 2017 Jun; 90():863-871. PubMed ID: 28437890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats.
    Elshazly SM
    Eur J Pharmacol; 2015 Feb; 748():123-32. PubMed ID: 25542756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
    Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
    J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes.
    Zabihi NA; Pirro M; Johnston TP; Sahebkar A
    Curr Pharm Des; 2017; 23(7):969-982. PubMed ID: 27748192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis.
    Lukivskaya O; Zavodnik L; Knas M; Buko V
    Adv Med Sci; 2006; 51():54-9. PubMed ID: 17357278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effect of the extract of TCM Fructus akebiae combined with ursodeoxycholic acid on nonalcoholic fatty liver disease.
    Hongguang J; Xingjie H; Mingliang J; Yun L; Tongjian L; Jingmo Y; Liang L; Lifang Z
    Pak J Pharm Sci; 2019 Jan; 32(1(Special)):433-437. PubMed ID: 30852481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.